ClinicalTrials.gg
CompletedNCT01178853Updated Oct 8, 2012Results posted

Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers

A Phase 4 interventional study of Warfarin and Warfarin 5mg + Rosuvastatin 40 mg once daily (QD) in Healthy, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-08.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 4, single center, open label, 4 period, 2 treatment, crossover, drug-drug interaction study.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a healthy adult male or female volunteer aged 18 to 45 years, inclusive
  • Subject has a of 18 to 32 kg/m2, inclusive
  • Subject is able and willing to abstain from alcohol, grapefruit, caffeine
  • Subject has no abnormalities on the basis of medical history, physical examination, and vital signs

Exclusion criteria

Exclusion Criteria:

  • Subject has out-of-range (PT), activated partial thromboplastin time, fibrinogen, protein C, or protein S
  • Subject has abnormal prolongation of bleeding time at Screening
  • Subject has hematuria on urinalysis
  • Subject has personal or family history of coagulation or bleeding disorders
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Pitavastatin/Rosuvastatin

    Drug: Warfarin · Drug: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD) · Drug: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)

  • Experimental
    Rosuvastatin/Pitavastatin

    Drug: Warfarin · Drug: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD) · Drug: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)

Interventions

  • Warfarin 5 mg once daily

  • DrugWarfarin 5mg + Rosuvastatin 40 mg once daily (QD)

    Drug page: Warfarin

    Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)

  • DrugWarfarin 5 mg + Pitavastatin 4mg once daily (QD)

    Drug page: Warfarin

    Warfarin 5 mg + Pitavastatin 4mg

06

What researchers measure

Primary outcomes

  1. Percent Mean Change From Baseline of International Normalized Ratio (INR)

    INR is the ratio of a patient's prothrombin time to a standard, raised to the power of the ISI value for the tissue factor reagent used (INR = (PT-Test/PT-Normal)\^ISI)

    Time frame: 22 Days

07

Results

Posted Oct 8, 2012

Participant flow

14 July 2010 - 09 November 2010

Period 1 (Warfarin Titration)
Participant flow — Period 1 (Warfarin Titration)
MilestonePitavastatin/RosuvastatinRosuvastatin/Pitavastatin
Started2424
Completed2322
Not completed12
Withdrew: Inr out of range12
Period 2 (Warfarin + Study Drug)
Participant flow — Period 2 (Warfarin + Study Drug)
MilestonePitavastatin/RosuvastatinRosuvastatin/Pitavastatin
Started2322
Completed2222
Not completed10
Withdrew: Withdrawal by subject10
Period 3 (Warfarin Titration)
Participant flow — Period 3 (Warfarin Titration)
MilestonePitavastatin/RosuvastatinRosuvastatin/Pitavastatin
Started2222
Completed2122
Not completed10
Withdrew: Adverse event10
Period 4 (Warfarin + Study Drug)
Participant flow — Period 4 (Warfarin + Study Drug)
MilestonePitavastatin/RosuvastatinRosuvastatin/Pitavastatin
Started2122
Completed2119
Not completed03
Withdrew: Adverse event02
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercent Mean Change From Baseline of International Normalized Ratio (INR)

INR is the ratio of a patient's prothrombin time to a standard, raised to the power of the ISI value for the tissue factor reagent used (INR = (PT-Test/PT-Normal)\^ISI)

Time frame:
22 Days
Reported as:
Mean · percent change
Percent Mean Change From Baseline of International Normalized Ratio (INR)
percent changeWarfarin + PitavastatinWarfarin + Rosuvastatin
Percent Mean Change From Baseline of International Normalized Ratio (INR)0.0452 ± 2.610.1605 ± 9.43

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Warfarin + Pitavastatin—0/42 (0%)6/42 (14.3%)
Warfarin + Rosuvastatin—0/43 (0%)3/43 (7%)
Most frequent other events
Most frequent other events
EventWarfarin + PitavastatinWarfarin + Rosuvastatin
NauseaGastrointestinal disorders3/423/43
HeadacheNervous system disorders3/420/43

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin/RosuvastatinRosuvastatin/PitavastatinTotal
<=18 years000
Between 18 and 65 years242448
>=65 years000
Age Continuous
Age Continuous(years)Pitavastatin/RosuvastatinRosuvastatin/PitavastatinTotal
Mean32.4 ± 7.834.1 ± 7.233.3 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin/RosuvastatinRosuvastatin/PitavastatinTotal
Female8816
Male161632
Region of Enrollment
Region of Enrollment(participants)Pitavastatin/RosuvastatinRosuvastatin/PitavastatinTotal
United States242448
08

Study locations

1 site
  • Austin, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Oct 2010 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2010
First posted
Aug 10, 2010
Start
Jul 2010
Primary completionActual
Oct 2010
CompletionActual
Apr 2011
Results first posted
Oct 8, 2012
Last update
Oct 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01178853
Responsible party
Sponsor
First posted
Aug 10, 2010
Start date
Jul 2010
Primary completion
Oct 2010
Completion
Apr 2011
Results posted
Oct 8, 2012
Last update
Oct 8, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Warfarin

Start the discussion